Advertisement
Julie Zhang
Reporter, Business
Julie Zhang joined SCMP in 2025 as a business reporter. She was formerly with China Daily Hong Kong Edition for over five years, covering corporate earnings, IPOs, financial regulations, ESG, cryptocurrency and property markets. Her reporting garnered multiple Hong Kong News Awards and Hang Seng University's Business Journalism Award.
Julie Zhang joined SCMP in 2025 as a business reporter. She was formerly with China Daily Hong Kong Edition for over five years, covering corporate earnings, IPOs, financial regulations, ESG, cryptocurrency and property markets. Her reporting garnered multiple Hong Kong News Awards and Hang Seng University's Business Journalism Award.
Areas of Expertise:
Corporate finance, IPOSLanguages Spoken:
Cantonese, English, Mandarin
Pharmaceutical contractor’s GLP-1 programmes and surging stock gains have made it a magnet for global investors.
Chinese mutual funds shifted focus amid market volatility, cutting their share of Hong Kong stocks to 23.3 per cent in the second quarter.
Analysts say that China’s pivot from generics to innovative drugs means the industry is less exposed to US levies.
Push to accelerate novel drug reviews promises earlier access to breakthrough therapies for patients long left waiting.
Advertisement
Axiom Biosciences founder says Hong Kong investors show greater maturity than Nasdaq in handling biotech companies.
Home-grown therapies account for 80 per cent of approvals in first six months of the year.
Chinese gold producers, after a buying spree for mines abroad, are cashing in as the metal’s price goes sky-high.
Analysts say valuation of the sector is attractive, with biotech firms trading relatively cheaply.
Lab-grown diamond maker Power Diamond sees profits triple as De Beers warns of ‘protracted’ challenges in natural stone market.
Soaring profits at Tianqi and Ganfeng highlight how global demand for energy independence is powering China’s lithium edge.
Chinese medical device companies eye Europe for relief from hospital probes at home while navigating protectionism overseas.
China develops 30 per cent of new therapies worldwide as it rises to the top tier in innovation efficiency, drug supervision official says.
Bourse expected to see influx of international issuers in year’s second half, led by consumer goods and services companies, according to PwC.
Quota expanded to 500 billion yuan from Friday, with tenor increased to two to three years, up from one.
Global gold market trading volumes averaged a record US$488 billion per day during the first half of the year.
The rapid development of China’s RAS-targeted cancer drugs could reshape global oncology and unlock the country’s undervalued biotech firms.
Chief Executive John Lee announces ‘milestone’ for city’s gold trading ecosystem at Hong Kong FIC & Bond Connect Summit.
Hong Kong Monetary Authority widens scope of yuan finance to solidify status as ‘offshore laboratory’ for currency amid de-dollarisiation trend.
The city plans to process its first gold settlement on Tuesday, according to those familiar with the matter.
Global pharmaceutical firms are tapping into Chinese artificial intelligence assets before patents expire on blockbuster drugs, advancing AI-driven biotech.
Beijing’s anti-tax evasion campaign could expand, raising concerns that corporate earnings, cash flows and investor sentiment may be at risk.
The trend reflects a ‘growing relevance’ of Asian markets, while US investors pull back on gold holdings due to higher rates, inflation.
Royalty financing offers new cash source as global investors pursue Chinese drug breakthroughs despite US pressure, Royalty Pharma says.
With Chinese technology giants fuelling an ‘A-to-H’ listing boom, Hong Kong appears to be on the rise as their ‘fundraising venue of choice’.
Likang Life Sciences says it has developed a personalised vaccine using advanced tech to identify tumour-specific mutations.
Calls grow to further expand Hong Kong’s connect scheme with mainland China markets amid drive for deeper capital flows.
Average daily southbound turnover soared 84 per cent year on year to HK$124.1 billion, equal to 24 per cent of city’s total market turnover.
The move comes after European Central Bank chief urged global leaders to discuss undervaluation of the Chinese currency.
Goldman Sachs says pharmaceutical, biotech sectors could see strongest tailwinds, while car industry, tech hardware makers may struggle.
